AI Article Synopsis
- The use of vaccinia virus in recombinant systems can lead to complications similar to those seen with smallpox vaccinations.
- A survey conducted in the USSR from 1968 to 1979 revealed significant complication rates, especially among older primary vaccinees.
- The high incidence of neurological issues in individuals aged 5 years and older suggests that these complications will restrict the application of vaccinia virus in recombinant technology.
Article Abstract
The use of vaccinia virus in recombinant systems may result in the occurrence of complications observed following smallpox vaccination. The results are presented of a large survey carried out in the USSR between 1968 and 1979. High complication rates are reported, particularly in older primary vaccinees; for example, there were 312.5 cases of neurological complications per million in those aged greater than or equal to 5 years. The author concludes that this factor will limit the use of vaccinia virus in recombinant technology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0264-410x(92)90023-d | DOI Listing |
Publication Analysis
Top Keywords
vaccinia virus
8
virus recombinant
8
age-dependent risk
4
risk postvaccination
4
postvaccination complications
4
complications vaccinees
4
vaccinees smallpox
4
smallpox vaccine
4
vaccine vaccinia
4
recombinant systems
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!